Ascletis Unveils Promising Obesity Treatment Advances at ADA 2026

Ascletis Pharma Inc. recently made waves at the American Diabetes Association (ADA) 2026 Scientific Sessions held from June 5-8 in New Orleans, Louisiana. The biotechnology firm highlighted groundbreaking clinical data from three significant studies focusing on innovative treatments for obesity. The emphasis was on their differentiated portfolio, which includes both oral small-molecule candidates and advanced peptide solutions.

Key Research Highlights

1. Oral Amylin Receptor Agonist: ASC39

One of the standout presentations was about ASC39, a potent oral amylin receptor agonist. Preclinical results indicated that ASC39 has a high selectivity for the human amylin type 1 receptor (hAMY1R), which is critical in minimizing potential side effects commonly experienced with less selective compounds. In a rat model simulating diet-induced obesity (DIO), dosing of ASC39 produced compelling results: the 5 mg/kg group experienced a remarkable 9.9% reduction in body weight, significantly outperforming the placebo group. Additionally, a head-to-head comparison against eloralintide—the current standard—showed ASC39 had a more rapid and pronounced effect on weight loss, establishing it as a promising candidate for further development in obesity therapies.

2. Advanced GLP-1 Receptor Agonist: ASC30

The presentation of ASC30, an oral GLP-1 receptor (GLP-1R) agonist, drew significant interest. ASC30 has shown to be 2-3 times more potent than its predecessor, orforglipron. Key findings from non-human primate studies revealed that ASC30 prompted a significantly higher insulin secretion compared to OFG. In terms of safety and efficacy, ASC30 demonstrated a favorable profile in a Phase II trial, whereby participants showed a consistent dose-dependent reduction in body weight, with no plateau observed. Given that global Phase III trials are anticipated to kick off by the end of Q3 2026, there is a considerable excitement surrounding its potential as a best-in-class obesity management solution.

3. Novel Triple Agonist Peptide: ASC37

The final highlight came from ASC37, an oral triple agonist peptide that works on GLP-1R, GIPR, and GCGR pathways. Utilizing Ascletis' proprietary Peptide Oral Transport ENhancement Technology (POTENT), ASC37 demonstrated impressive bioavailability, achieving up to five times greater effectiveness compared to existing formulations of similar peptides. This innovative approach to oral delivery could revolutionize treatment protocols for patients living with obesity and metabolic disorders.

Conclusion

Ascletis has reinforced its reputation as a leading innovator in metabolic disease therapeutics through its comprehensive range of obesity treatment candidates. The results presented at the ADA 2026 underline the potential of ASC30, ASC37, and ASC39 to pave the way toward effective, patient-friendly therapies. As these candidates move toward late-stage clinical trials, the anticipation for their availability grows, promising a brighter future for individuals struggling with obesity.

For more details on Ascletis and their ongoing research, visit www.ascletis.com.